Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xlife Sciences AGXSWX:XLS -3.51%52 3-Year Book Growth Rate is 3.70% as of Dec. 2025, which is 76% below its 10-year median of 15.30. GuruFocus rates XSWX:XLS with a GF Score™ of 52/100 and a GF Value™ of CHF7.16 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,134 Biotechnology companies, Xlife Sciences AG ranks better than 68.87% on this metric.
During the past 12 months, Xlife Sciences AG's average Book Value per Share Growth Rate was -6.60% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 8 years, the highest 3-Year average Book Value per Share Growth Rate of Xlife Sciences AG was 21.40% per year. The lowest was 3.70% per year. And the median was 15.30% per year.
Xlife Sciences AG (XSWX:XLS) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Xlife Sciences AG 3-Year Book Growth Rate Related Terms
XSWX:XLS vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Xlife Sciences AG's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's 3-Year Book Growth Rate falls into.
Xlife Sciences AG 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 3.70% mean?
Xlife Sciences AG (XSWX:XLS) has a 3-Year Book Growth Rate of 3.70% as of Dec. 2025. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Xlife Sciences AG and its competitors. This is 76% below median its historical median of 15.30. Over the past decade, Xlife Sciences AG's 3-Year Book Growth Rate has ranged from 3.70 to 21.40. According to the industry distribution chart, Xlife Sciences AG ranks #353 out of 1134 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Xlife Sciences AG's 3-Year Book Growth Rate too high?
Xlife Sciences AG's current 3-Year Book Growth Rate of 3.70% is 76% below median its 10-year median of 15.30. Over the past 10 years, this metric has ranged from a low of 3.70 to a high of 21.40. Based on the distribution chart, Xlife Sciences AG ranks #353 out of 1134 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #353 out of 1134 companies for 3-Year Book Growth Rate. This puts Xlife Sciences AG in the upper half of its industry. Historically, Xlife Sciences AG's own 3-Year Book Growth Rate has ranged from 3.70 to 21.40 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Xlife Sciences AG and its competitors. Xlife Sciences AG's current 3-Year Book Growth Rate is 3.70%, which is 76% below median its own 10-year median of 15.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.16, compared to a current price of CHF16.50 — trading 130.4% above its estimated fair value. The current 3-Year Book Growth Rate is 3.70%, which is 76% below median its 10-year median of 15.30. Xlife Sciences AG's overall GF Score™ is 52/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current 3-Year Book Growth Rate is 3.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF16.50 is trading 130.4% above its estimated GF Value™ of CHF7.16.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
3-Year Book Growth Rate: 3.70% (76% below median its 10-year median of 15.30)
GF Value™: CHF7.16 vs. price of CHF16.50 (130.4% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
52GF Score
Get the complete analysis for XSWX:XLS
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
